Developer docs
API playgroundTry for free, no card

Search company profiles

NIOX

Full company profile

uuid000batq

Namestring
NIOX
Legal namestring
NIOX Group plc
Websiteurl
niox.com
Company typeenum
Public
Founded yearint
1998
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory diagnostics devices, FeNO testing equipment, electrochemical medical sensors, point-of-care diagnostics, asthma management technology
Industry2 codes
PRIMARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Respiratory Diagnostic Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical FeNO Testing
TypeHardware Sales
Description

Primary revenue stream from clinical FeNO testing devices and sensors. H1 2026 clinical revenue grew to £20.6m from £20.0m, representing strategic prioritization of the clinical business over research operations.

investing.com
2Research FeNO Testing
TypeHardware Sales
Description

Revenue from research sector FeNO testing declined to £3.4m following strategic shift to prioritize clinical business inventory allocation. Represents historical strength in research market with device of choice in thousands of clinical trials globally.

za.investing.com
3Sensor Supply Agreement
TypeSubscription Recurring
Description

10-year exclusive sensor supply agreement secured, providing long-term recurring sensor revenue stream from replacement sensors for installed device base.

investing.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Pricing details1 tier
1NIOX VERO device and sensors - pricing by quote
ModelOtherBilling cadencePay-as-you-go
Notes

Device pricing provided via online quote request. Sensors require periodic replacement after specified number of measurements. No public pricing listed on website.

niox.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1NIOX VERO
Description

Gold standard FeNO testing device for measuring fractional exhaled nitric oxide in patients with asthma

niox.com
+5 more records
Core offering1 text field

NIOX manufactures and sells handheld electrochemical medical devices that measure fractional exhaled nitric oxide (FeNO) at the point of care to support the diagnosis and management of asthma. The NIOX VERO and NIOX PRO devices are sold primarily to healthcare professionals in primary care, secondary care, research, and pharmacy settings, with recurring revenue from replacement sensors under a 10-year exclusive supply agreement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 50% reduction in asthma exacerbations with FeNO-guided management during pregnancy
+4 more records
Product overview1 text field

NIOX Group plc is a medical technology company specializing in respiratory diagnostics, specifically fractional exhaled nitric oxide (FeNO) testing for asthma diagnosis and management. The company pioneered FeNO testing in 1998 and offers a portfolio of handheld electrochemical FeNO testing devices, software platforms, and educational tools. The core product is the NIOX VERO® handheld device for point-of-care FeNO measurement, complemented by the NIOX PRO® clinical device (CE Mark and UK MHRA approved in 2026), NIOX Cloud™ data management platform, and the FeNO Learn educational app. Additional offerings include the nioxOS® operating system, patient-facing FeNO for Me portal, augmented reality demo tools, multilingual website translation via NIOX Lingua™, and extensive educational content including webinars, masterclasses, case studies, and a podcast series.

Product and service5 records
1NIOX VERO®
CategoryClinical diagnostic device
Description

Flagship handheld electrochemical FeNO (fractional exhaled nitric oxide) testing device for point-of-care diagnosis and monitoring of asthma in primary and secondary care settings, with touchscreen interface and Flow Rate Control technology including child compatibility mode.

2NIOX PRO®
CategoryClinical diagnostic device
Description

Professional-grade FeNO testing device for clinical settings, expanding NIOX's clinical product portfolio alongside NIOX VERO. CE Mark and UK MHRA approved.

3NIOX Cloud™
CategoryCloud data platform
Description

Cloud-based data management and connectivity platform for NIOX devices, enabling data storage and remote monitoring of FeNO testing results.

4FeNO Learn
CategoryEducational platform
Description

Mobile application (iOS and Google Play) and web-based educational platform providing healthcare professionals with courses, webinars, case studies, masterclasses, and an interpreting FeNO tool to support FeNO testing education.

5NIOX Replacement Sensors
CategoryDevice consumables
Description

Pre-calibrated electrochemical sensors for use with NIOX VERO and NIOX PRO devices, supplied under a 10-year exclusive sensor supply agreement as a recurring consumable revenue stream.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

ResMed acquired BreathSmart in March 2025 to expand its digital therapeutics platform. Competitive context - ResMed is a major player in respiratory device market but no direct partnership with NIOX mentioned.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

Philips collaboration with Oventus Medical (November 2024) in sleep and respiratory care. Competitive context - industry collaboration in respiratory device space.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Partnership with NHS England Accelerated Access Collaborative (AAC) Rapid Uptake Programme to improve patient outcomes through FeNO testing integration in primary care. Programme resulted in 58,000 new asthma diagnoses, 1,244 devices deployed in primary care, 53% of primary care networks gaining FeNO access, and nearly 5,000 hours of training completed. Supported by £915,000 AAC Pathway Transformation Fund across 33 projects.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bedfont's NObreath is a handheld FeNO device used by clinicians for asthma assessment, making it the closest direct commercial competitor to NIOX VERO.

TypeDirect peer
Description

Bosch's Vivatmo pro is an electrochemical FeNO testing system targeting the same primary care and specialist clinicians as NIOX, with comparable point-of-care workflow.

TypeDirect peer
Description

Medisoft manufactures FeNO analyzers (HypAir FeNO) used in clinical and research respiratory diagnostics, overlapping directly with NIOX on technology and customer base.

TypeDirect peer
Description

Eco Medics builds chemiluminescence-based exhaled nitric oxide analyzers used as reference instruments against which NIOX sensors are calibrated, competing for the same respiratory research and clinical market.

5Aerocrine (Circassia)
TypeDirect peer
Description

Aerocrine originally commercialised the NIOX technology and was acquired by Circassia; Circassia retains a respiratory diagnostics franchise competing in FeNO and adjacent airway inflammation testing.

TypeBroad incumbent
Description

Global leader in sleep and respiratory care that acquired BreathSmart in March 2025, signalling expansion into connected respiratory diagnostics adjacent to NIOX's point-of-care testing.

TypeBroad incumbent
Description

Broad respiratory and sleep portfolio including ventilators and connected care; its collaboration with Oventus Medical (November 2024) increases competitive pressure on niche players like NIOX.

TypeBroad incumbent
Description

Pulmonx provides interventional pulmonology diagnostics and serves the same hospital-based respiratory specialists that NIOX targets in secondary care for severe asthma assessment.

TypeEmerging player
Description

MGC Diagnostics supplies pulmonary function and FeNO-related testing equipment, partially overlapping NIOX's offerings across respiratory diagnostics workflows.

TypeOthers
Description

Major biologic manufacturer in severe asthma (eosinophilic and Type 2 inflammation); NIOX's severe-asthma and biologic-selection use case is directly adjacent to AZ's commercial franchise, making AZ a strategic partner/competitor.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NIOX

Respiratory Diagnostic Devicesniox.com

NIOX firmographics

Firmographics
Name
NIOX
Legal name
NIOX Group plc
Website
https://niox.com
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

NIOX industry classification

Industry
Product category
Respiratory Diagnostic Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Respiratory diagnostics devices
  • FeNO testing equipment
  • Electrochemical medical sensors
  • Point-of-care diagnostics
  • Asthma management technology

Where NIOX is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

NIOX business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Clinical FeNO Testing: Primary revenue stream from clinical FeNO testing devices and sensors. H1 2026 clinical revenue grew to £20.6m from £20.0m, representing strategic prioritization of the clinical business over research operations.
  2. Research FeNO Testing: Revenue from research sector FeNO testing declined to £3.4m following strategic shift to prioritize clinical business inventory allocation. Represents historical strength in research market with device of choice in thousands of clinical trials globally.
  3. Sensor Supply Agreement: 10-year exclusive sensor supply agreement secured, providing long-term recurring sensor revenue stream from replacement sensors for installed device base.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNIOX VERO device and sensors - pricing by quote

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

NIOX product offering

Product offering

Core offering

NIOX manufactures and sells handheld electrochemical medical devices that measure fractional exhaled nitric oxide (FeNO) at the point of care to support the diagnosis and management of asthma. The NIOX VERO and NIOX PRO devices are sold primarily to healthcare professionals in primary care, secondary care, research, and pharmacy settings, with recurring revenue from replacement sensors under a 10-year exclusive supply agreement.

Product overview

NIOX Group plc is a medical technology company specializing in respiratory diagnostics, specifically fractional exhaled nitric oxide (FeNO) testing for asthma diagnosis and management. The company pioneered FeNO testing in 1998 and offers a portfolio of handheld electrochemical FeNO testing devices, software platforms, and educational tools. The core product is the NIOX VERO® handheld device for point-of-care FeNO measurement, complemented by the NIOX PRO® clinical device (CE Mark and UK MHRA approved in 2026), NIOX Cloud™ data management platform, and the FeNO Learn educational app. Additional offerings include the nioxOS® operating system, patient-facing FeNO for Me portal, augmented reality demo tools, multilingual website translation via NIOX Lingua™, and extensive educational content including webinars, masterclasses, case studies, and a podcast series.

Differentiator

Problem solved

Functional benefit

Brands

  • NIOX VERO: Gold standard FeNO testing device for measuring fractional exhaled nitric oxide in patients with asthma
  • NIOX PRO
  • FeNO Learn
  • nioxOS
  • NIOX Cloud
  • NIOX Lingua

Products and services

  • NIOX VERO® Flagship handheld electrochemical FeNO (fractional exhaled nitric oxide) testing device for point-of-care diagnosis and monitoring of asthma in primary and secondary care settings, with touchscreen interface and Flow Rate Control technology including child compatibility mode.
  • NIOX PRO® Professional-grade FeNO testing device for clinical settings, expanding NIOX's clinical product portfolio alongside NIOX VERO. CE Mark and UK MHRA approved.
  • NIOX Cloud™ Cloud-based data management and connectivity platform for NIOX devices, enabling data storage and remote monitoring of FeNO testing results.
  • FeNO Learn Mobile application (iOS and Google Play) and web-based educational platform providing healthcare professionals with courses, webinars, case studies, masterclasses, and an interpreting FeNO tool to support FeNO testing education.
  • NIOX Replacement Sensors Pre-calibrated electrochemical sensors for use with NIOX VERO and NIOX PRO devices, supplied under a 10-year exclusive sensor supply agreement as a recurring consumable revenue stream.

Quantifiable outcome

  • 50% reduction in asthma exacerbations with FeNO-guided management during pregnancy
  • +4 more outcomes

Companies that use NIOX

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

NIOX technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

NIOX partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and flagship.

  • ResMedminorStrategic or Co-development Partner · 1 March 2025ResMed acquired BreathSmart in March 2025 to expand its digital therapeutics platform. Competitive context - ResMed is a major player in respiratory device market but no direct partnership with NIOX mentioned.
  • Philips HealthcareminorStrategic or Co-development Partner · 1 November 2024Philips collaboration with Oventus Medical (November 2024) in sleep and respiratory care. Competitive context - industry collaboration in respiratory device space.
  • Wessex Academic Health Science Network (AHSN)flagshipStrategic or Co-development Partner · 1 March 2021Partnership with NHS England Accelerated Access Collaborative (AAC) Rapid Uptake Programme to improve patient outcomes through FeNO testing integration in primary care. Programme resulted in 58,000 new asthma diagnoses, 1,244 devices deployed in primary care, 53% of primary care networks gaining FeNO access, and nearly 5,000 hours of training completed. Supported by £915,000 AAC Pathway Transformation Fund across 33 projects.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

NIOX competitors and assessment

Company assessment

Direct peers

  • Bedfont Scientific: Bedfont's NObreath is a handheld FeNO device used by clinicians for asthma assessment, making it the closest direct commercial competitor to NIOX VERO.
  • Bosch Healthcare Solutions: Bosch's Vivatmo pro is an electrochemical FeNO testing system targeting the same primary care and specialist clinicians as NIOX, with comparable point-of-care workflow.
  • Medisoft: Medisoft manufactures FeNO analyzers (HypAir FeNO) used in clinical and research respiratory diagnostics, overlapping directly with NIOX on technology and customer base.
  • Eco Medics: Eco Medics builds chemiluminescence-based exhaled nitric oxide analyzers used as reference instruments against which NIOX sensors are calibrated, competing for the same respiratory research and clinical market.
  • Aerocrine (Circassia): Aerocrine originally commercialised the NIOX technology and was acquired by Circassia; Circassia retains a respiratory diagnostics franchise competing in FeNO and adjacent airway inflammation testing.

Broad incumbents

  • ResMed: Global leader in sleep and respiratory care that acquired BreathSmart in March 2025, signalling expansion into connected respiratory diagnostics adjacent to NIOX's point-of-care testing.
  • Philips Healthcare: Broad respiratory and sleep portfolio including ventilators and connected care; its collaboration with Oventus Medical (November 2024) increases competitive pressure on niche players like NIOX.
  • Pulmonx: Pulmonx provides interventional pulmonology diagnostics and serves the same hospital-based respiratory specialists that NIOX targets in secondary care for severe asthma assessment.

Emerging players

Others

  • AstraZeneca: Major biologic manufacturer in severe asthma (eosinophilic and Type 2 inflammation); NIOX's severe-asthma and biologic-selection use case is directly adjacent to AZ's commercial franchise, making AZ a strategic partner/competitor.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

NIOX social profiles

Digital presence

NIOX compliance and trust

Trust signal

Compliance2 records

NIOX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NIOX leadership team

Management profile

Number of profiles

Profiles4 records

NIOX subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

NIOX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NIOX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIOX

What does NIOX do?

NIOX manufactures and sells handheld electrochemical medical devices that measure fractional exhaled nitric oxide (FeNO) at the point of care to support the diagnosis and management of asthma. The NIOX VERO and NIOX PRO devices are sold primarily to healthcare professionals in primary care, secondary care, research, and pharmacy settings, with recurring revenue from replacement sensors under a 10-year exclusive supply agreement.

Is NIOX a public or private company?

NIOX is a public company. It is classified as public and is currently operating.

When was NIOX founded?

NIOX was founded in 1998. It employs 101 to 250 people.

Where is NIOX based?

NIOX is headquartered in Oxford, United Kingdom, in the Europe region.

How does NIOX make money?

Three revenue lines are on record. Clinical FeNO Testing is the primary driver. The others are research FeNO Testing and sensor Supply Agreement.

Who are NIOX's main competitors?

Direct peers on record are Bedfont Scientific, Bosch Healthcare Solutions, Medisoft, Eco Medics and Aerocrine (Circassia). Broad incumbents are ResMed, Philips Healthcare and Pulmonx. MGC Diagnostics (Medical Graphics / Spirosure) is listed as an emerging player. AstraZeneca is listed as an others.

Does NIOX have an API?

No public API is recorded for NIOX.

What industry is NIOX in?

NIOX's product category is Respiratory Diagnostic Devices. Its primary akta.pro industry code is HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate), with a secondary code of HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Yahoo3 British Healthcare Stocks With Revenue Growth Up To 13%Three British healthcare stocks—NIOX Group, HUTCHMED (China), and AstraZeneca—are highlighted for revenue growth up to 13%. NIOX Group generates about £47.5 million from its NIOX VERO device, HUTCHMED has US$237 million from marketed oncology products, and AstraZeneca reports US$62.4 billion in pharmaceutical revenue.InvestegateDirector/PDMR Shareholding & RPT UpdateNIOX Group plc announced that its directors participated in the company's tender offer, reducing their shareholdings. Harwood Capital, a substantial shareholder, tendered 4,336,495 shares, deemed a related-party transaction. The independent directors consider the terms fair and reasonable.TradingViewREG - Niox Group PLC AstraZeneca PLC - Holding(s) in CompanyAstraZeneca PLC notified the FCA of crossing the major holdings threshold in Niox Group PLC on 22 October 2026, holding 16.31% of voting rights (66,093,108 shares). The stake rose from 15.86% in the previous notification, and the notification was completed on 26 October 2026.InvestegateResult of General MeetingNIOX Group plc's General Meeting passed the Tender Offer Resolution on a poll of votes, with 99.17% of votes in favor. The results were announced on 21 October 2026, and the outcome of the tender offer will be announced on 22 October 2026.YahooTop 3 British Healthcare Stocks To Watch In October 2026The article profiles three British healthcare stocks: NIOX Group, HUTCHMED, and Integrated Diagnostics Holdings. NIOX generates £47.5 million from its NIOX segment, HUTCHMED reported $237 million from marketed oncology products, and Integrated Diagnostics Holdings has a market value of about US$305 million. Each faces pricing and access pressures that could affect future growth.Markets DailyNIOX Group (LON:NIOX) Posts Earnings ResultsNIOX Group reported quarterly earnings of GBX 1.41 per share, with a return on equity of 10.14% and a net margin of 14.37%. The stock rose GBX 0.40 to GBX 68.40 during trading, and the company operates non-invasive diagnostic products for asthma and COPD.Investing.comNIOX Group reports H1 revenue of £24m, plans capital return By Investing.comNIOX Group plc reported H1 2026 revenue of £24.0m, down from £25.2m in the prior year period, with clinical revenue growing to £20.6m while research revenue declined to £3.4m following a strategic shift toward the clinical business. The company secured CE Mark and UK MHRA approvals for its NIOX PRO device, signed a 10-year exclusive sensor supply agreement, and implemented a pricing increase in Japan from June 1, 2026, with regulatory submissions still pending in the United States and Japan. The board intends to return excess capital to shareholders during the second half of 2026, with the company trading in line with full-year consensus expectations.Investing.comNIOX Group reports H1 revenue of £24m, plans capital return By Investing.comNIOX Group reported H1 2026 revenue of £24.0m, down from £25.2m in the prior-year period, with adjusted EBITDA declining to £8.3m from £9.2m, despite clinical revenue rising to £20.6m from £20.0m. The company obtained CE Mark and UK MHRA approval for its NIOX PRO device, signed a 10-year exclusive sensor supply agreement, and implemented a pricing increase in Japan following a reimbursement increase. The board stated it intends to return excess capital to shareholders during H2 2026, with the company holding net cash of £16.8m after paying a £6.5m dividend.Defense WorldNIOX Group (LON:NIOX) Insider Jonathan Emms Sells 325,273 SharesNIOX Group (LON:NIOX) insider Jonathan Emms sold 325,273 shares at an average price of GBX 56, generating a total transaction value of £182,152.88 on Thursday, April 16th. The stock was trading up 1.4% following the transaction, with Deutsche Bank simultaneously lowering its target price from GBX 90 to GBX 86 while maintaining a "buy" rating on the shares. NIOX Group is a UK-headquartered medical technology company focused on respiratory diagnostics, operating in over 50 countries.Financial TimesHolding(s) in Company – Company AnnouncementAstraZeneca UK Limited notified Niox Group PLC of a major holding, crossing the 15% threshold on 20 May 2025. The notification, dated 13 June 2025, shows a 15.86% stake in 66,093,108 ordinary shares.